Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Pipeline Insights, 2016

  • ID: 3774301
  • Drug Pipelines
  • 40 pages
  • DelveInsight
1 of 4
“Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4)-Pipeline Insights, 2016” provides comprehensive insights about pipeline drugs across this indication. Key objective of the report is to establish the understanding for all the pipeline drugs that fall under Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4). This report provides information on the therapeutic development based on the Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) dealing with all the pipeline drugs, comparative analysis of Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4)at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the company’s information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Note: This report will be delivered to the client in 48 hours

Reports Highlights:
- Delta-like ligand 4 Therapy Pipeline scenario
- Collaborations & partnering deals
- Current Prominent Research Areas and Key Players
- Pipeline product profiles Delta-like ligand 4Technologies and Targeted Antigens
- Licensing opportunities
- Market Drivers and Barriers
Note: Product cover images may vary from those shown
2 of 4
Table of Contents

- Overview
- Technical Analysis
- Pipeline Therapeutics
- Therapeutics under Development by Companies
- Mid Stage Products (Phase II)
- Comparative Analysis
- Early Stage Products (Phase I)
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Dormant Products
- Comparative Analysis
- Companies involved in Therapeutics Development
- Appendix
- Methodology
- Consulting Services
- About us
- Contact Us
- Disclaimer

List of Tables

Table 1:Number of Products Under Development for Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4),2016
Table 2: Number of Products under Development by Companies, 2016
Table 3: Mid Stage Products (Phase II),2016
Table 4: Early Stage Products (Phase I), 2016
Table 5:Number of Products Under Development for Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4),2016
Table 6: Assessment by Route Of Administration, 2016
Table 7:Assessment by Stage and Route Of Administration, 2016
Table 8: Assessment by Molecule Type, 2016
Table 9: Assessment by Stage and Molecule Type, 2016
Table 10: Dormant Products, 2016

List of Figures

Figure 1: Number of Products under Development forDelta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4), 2016
Figure 2: Mid Stage Products (Phase II), 2016
Figure 3:Early Stage Products (Phase I), 2016
Figure 4: Number of Products under Development for Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4),2016
Figure 5: Assessment by Route of Administration, 2016
Figure 6: Assessment by Stage and Route of Administration, 2016
Figure 7: Assessment by Molecule Type,2016
Figure 8: Assessment by Stage and Molecule Type,2016
Figure 9: Dormant Products, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- OncoMed
- MedImmune
- AbbVie
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll